Peptide Therapeutics - Global Market Outlook (2021 - 2028)

Peptide Therapeutics - Global Market Outlook (2021 - 2028)

According to Stratistics MRC, the Global Peptide Therapeutics Market is accounted for $31.93 billion in 2021 and is expected to reach $56.52 billion by 2028 growing at a CAGR of 8.5% during the forecast period. Peptides are the combination of two or more amino acid monomers linked by amide bonds. Researchers have demonstrated that peptide is distinguished from proteins on the basis of size. As a benchmark, molecules with less than 50 amino acids are considered as peptides. Peptides act by binding to specific cell surface receptors and mimics like receptor ligands and help in treatment of diseases by acting on the cell membrane. Peptides initially had applications only in diagnostics and hormonal therapy; however, with advances in technology, peptides are now being widely applied for therapeutic applications of cancer and chronic metabolic diseases.

Market Dynamics:

Driver:

Rising prevalence of chronic diseases

The major factor driving the market growth is the increasing prevalence of cancer and metabolic disorders along with the technological advancements in peptide therapeutics. According to the World Health Organization (WHO), chronic diseases, such as cancer, cardiovascular diseases, and diabetes, are the leading causes of death and disability worldwide. Disease rates from chronic conditions are accelerating globally, advancing across every region and pervading all socioeconomic classes. In 2020, the contribution of chronic diseases was estimated to have caused 73% of all deaths and 60% of the global burden of diseases. Thus, the increasing incidence of chronic diseases accelerates the need for effective therapeutics, which in turn, is expected to drive the growth of the peptide therapeutics market.

Restraint:

Instability of peptides

One of the true drawbacks of peptide drugs is the increased proteolytic instability compared to not only small molecules but also monoclonal antibody therapeutics. The Fc fragment of monoclonal antibodies reshuffle the protein to cells and peptide-Fc conjugates may also be protected from enzymatic cleavage. Chemically, both the amide bond and the side-chains can be altered to render the resulting peptidomimetics resistant to proteolytic degradation. The serum stability assay provides a ready measure of peptide stability and was once considered the most significant secondary screening tool in drug development. Indeed, serum stability can provide a strong prediction of the all-important pharmacokinetic behavior of drugs. Chemical instability involves damage of the primary structure, covalent modification of the protein through bond formation or cleavage.

Opportunity:

Growing adoption of synthetic peptide drugs

Synthetic peptide drugs can be made to look like naturally occurring peptides and can be used to treat cancer and other serious illnesses. Synthetic peptides are chemically synthesized small polymers of amino acids. Synthetic peptides are used as affinity ligands. Several companies are capable of synthesizing peptides of up to 100 amino acid residues as a custom peptide synthesis service. Peptides are nowadays readily available by synthetic methodologies and can be produced in large quantities at low cost. They are obtained as defined and pure chemical entities, eliminating variability in biological results, and their use is devoid of infection and immunogenic risks. For instance, Hemmo has been supplying peptide products and custom peptide synthesis for more than 38 years, making it one of India's major makers of synthetic peptide drugs provider.

Threat:

Stringent regulatory challenges

The increasing interest of the pharmaceutical industry in peptide therapeutics has been a catalyst for the development of regulations in this area. Nevertheless, manufacturers and regulators continue to encounter scientific and regulatory challenges when dealing with peptides as active pharmaceutical ingredients in drug products. Being at the borderline between typical small molecules and large proteins, peptides have raised a series of regulatory challenges. Since there are various peptide conjugate candidates that contain peptides in combination with small molecules, the regulatory aspect for peptide is still evolving. The FDA takes into account the history and manufacturing aspect of the candidate molecule to decide its regulatory pathway Example whether BLA would be submitted or NDA needs to be applied. Disparities in interpretation and application of existing International Council for Harmonisation (ICH) and United States Food and Drug Administration (FDA) regulatory guidances have resulted in challenges, inconsistencies, and confusion for both regulators and drug developers.

The cancer segment is expected to be the largest during the forecast period

The cancer segment is estimated to have a lucrative growth. Peptides offer favorable prospects in targeted drug delivery for cancer due to their high specificity, discernment, small sizes, ease of modification, and high biocompatibility. The increasing frequency of cancer globally and increasing prescription of peptide therapeutics for cancer treatment are the key factors responsible for the dominance of this segment. Moreover, the high prevalence of cancer cases globally is expected to play a vital role in the growth of the studied segment over the forecast period. Furthermore, rising awareness among patients and healthcare professionals regarding the adverse effects of chemotherapy and radiation therapy is a major factor for the growing focus on alternative therapeutics such as peptide-based drugs.

The oral segment is expected to have the highest CAGR during the forecast period

The oral segment is anticipated to witness the fastest CAGR growth during the forecast period. Due to a decrease in non-peptide chemical medications accessible in the market, sales of peptide therapeutic companies are currently rising. As peptides are a common component of food, both, the stomach and intestines contain a plethora of enzymes that can break them down, and most peptide-based drugs do not survive the gastrointestinal tract. The peptides generics market is expected to develop as the patent cliff rises. Because pharma businesses are shifting their focus to better potential in the peptide therapies sector, CMOs that provide end-to-end services to biotech pharmaceutical companies are rising. For instance, Heinis's Group is currently using a novel technology to develop oral peptide drugs that act directly on gastrointestinal targets, bypassing the bloodstream. Oral peptide drugs will play a crucial role in the treatment of a wide range of disorders.

Region with highest share:

North America is projected to hold the largest market share during the forecast period. North America is expected to dominate the overall market throughout the forecast period. The market growth is due to factors such as a rise in awareness levels relating to peptide therapeutic products, the increasing necessity for diagnostics in cancer and other diseases, and the growing biotechnology industry. A properly established biopharmaceutical and pharmaceutical industry in this region is a major factor responsible for growth. In the North American region, the United States holds the largest market share due to factors such as the increasing number of research programs in the medical industry and the growing number of diseases in the country, which is anticipated to stimulate the demand in this region. Owing to the increasing burden of cancer, the demand for peptide therapeutics is expected to grow. Hence, given the aforementioned factors, the peptide therapeutics market is expected to witness significant growth in North America over the forecast period.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period. Vast patient pool, increasing healthcare expenditure and demand for newer advanced therapies are key factors likely to boost peptide therapeutics market in Asia Pacific. Government funding for the use of peptides in the production of COVID-19 vaccines is expected to provide a potential incentive for the adoption of the peptides, potentially driving the growth of the APAC peptide therapeutics market.

Key players in the market

Some of the key players profiled in the Peptide Therapeutics Market include Bachem Holding AG, Bristol-Myers Squibb(BMS), Eli Lilly and Company, GlaxoSmithKline (GSK), ISSAR Pharmaceuticals, Lonza Inc, Merck & Co, Novartis AG, Novo Nordisk A/S, Pfizer Inc, Sanofi, Takeda Pharmaceutical Company Limited, and Xenetic Biosciences, Inc.

Key Developments:

In May 2021, ISSAR Pharmaceuticals took the decision to license out its peptide-based new chemical entities (NCEs) with pre-IND filing and the United States Patent for various unmet healthcare needs of the population, making it affordable and accessible for better health outcomes.

In July 2019, Xenetic Biosciences, Inc. completed acquisition of the novel CAR T (“Chimeric Antigen Receptor T Cell”) platform technology, called “XCART,” designed to use screening technique to identify peptide ligands that bind specifically to the unique B-cell receptor of malignant tumor cells.

Synthesis Technologies Covered:
Solid Phase Peptide Synthesis (SPPS)
Liquid Phase Peptide Synthesis (LPPS)
Hybrid Technology

Route of Administrations Covered:
Pulmonary
Parenteral
Oral
Mucosal
Injection
Other Route of Administrations

Types Covered:
Innovative
Generic
Branded

Type of Manufacturers Covered:
Outsourced
In-house
Contract Manufacturing Organizations (CMOs)

Type of Molecules Covered:
Vasopressin
Somatostatin
Natriuretic
Luteinizing Hormone (LH)-Releasing Hormone (LHRH)
Insulins
Immunopeptide
Glucagon and Analogs
Calcitonin

Applications Covered:
Acromegaly
Anti-infection
Cancer
Cardiovascular Disorder
Central Nervous System (Copaxone (Glatiramer))
Dermatology
Gastro-Intestinal Infection (GIT)
Hematological Disorders
Infection
Metabolic
Pain
Renal
Respiratory
Other Applications

End Users Covered:
Pharmaceutical and Biotechnology Industries
Hospitals
Contract Research Organization
Academic and Research Institutes
Regions Covered:
North America
US
Canada
Mexico
Europe
Germany
UK
Italy
France
Spain
Rest of Europe
Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
South America
Argentina
Brazil
Chile
Rest of South America
Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
Company Profiling
Comprehensive profiling of additional market players (up to 3)
SWOT Analysis of key players (up to 3)
Regional Segmentation
Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances